Indication: Chronic Lymphocytic Leukemia (CLL)

A Multi-Center, Open-Label, Study to Evaluate the Safety and Efficacy of Ublituximab (TG-1101) in Combination with TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304

Sub-indication: CLL/SLL

Line of Therapy: second line

Drug Study

Principal Investigator: Don Stevens, M.D.
Norton Cancer Institute

Sponsor: TG Therapeutics, Inc

Learn more at ClinicalTrials.gov

Email for more information: Heme-NCIResearch@nortonhealthcare.org

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.